Key Points – DarioHealth posted sequential revenue growth for the second straight quarter, with Q1 revenue rising to $5.6 million from $5.2 million in Q4 2025.
Operating losses and expenses also improved year over year, while the company ended the quarter with $20 million in cash and deposits. – Channel partnerships are driving growth: more than 80% of revenue now comes from partner-driven channels, and DarioHealth added 10 new accounts in Q1
Management said its pipeline was about $127 million across 241 open opportunities, with several larger accounts expected to launch later in 2026. – The company is expanding beyond digital engagement into care delivery and outcomes-based models by partnering with clinical providers and health systems. DarioHealth also highlighted its AI engine, DarioIQ, and said it remains active in a strategic review that could include a sale, merger, or continued standalone execution. – DarioHealth is an AI-Powered Digital Therapeutics Play DarioHealth (NASDAQ:DRIO) reported sequential revenue growth for the second straight quarter while outlining plans to expand its digital health platform further into care delivery, management said on the company’s first-quarter 2026 earnings call Wednesday. Chief Executive Officer Erez Raphael said the company entered 2026 with “continued momentum,” citing revenue growth, reduced operating expenses and progress converting 2025 commercial wins into revenue.
Management also highlighted a growing channel partner strategy, new account additions and plans to use DarioHealth’s data and artificial intelligence capabilities to support more outcomes-based and claims-related models. Revenue Rises Sequentially as Costs Decline In the company’s financial review, management said first-quarter revenue was $5.6 million, up from $5.2 million in the fourth quarter of 2025. The company said the year-over-year revenue decline from the first quarter of 2025 reflected a planned move away from non-recurring pharmaceutical…